Verastem Future Growth

Future criteria checks 0/6

Verastem is forecast to grow earnings and revenue by 49.6% and 57.7% per annum respectively while EPS is expected to grow by 52.6% per annum.

Key information

49.6%

Earnings growth rate

52.6%

EPS growth rate

Biotechs earnings growth	19.6%
Revenue growth rate	57.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	11 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0LOV - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	102	-55	-82	-113	6
12/31/2025	31	-117	-107	-117	7
12/31/2024	N/A	-130	-121	-121	7
12/31/2023	N/A	-87	-86	-86	N/A
9/30/2023	N/A	-77	-73	-73	N/A
6/30/2023	N/A	-75	-72	-72	N/A
3/31/2023	N/A	-73	-65	-65	N/A
12/31/2022	3	-74	-64	-64	N/A
9/30/2022	3	-73	-57	-57	N/A
6/30/2022	3	-78	-53	-53	N/A
3/31/2022	4	-73	-53	-53	N/A
12/31/2021	2	-71	-54	-54	N/A
9/30/2021	2	-75	-65	-65	N/A
6/30/2021	81	-39	-10	-10	N/A
3/31/2021	84	-45	-19	-19	N/A
12/31/2020	89	-68	-34	-34	N/A
9/30/2020	92	-87	-49	-49	N/A
6/30/2020	22	-130	-122	-122	N/A
3/31/2020	21	-149	-134	-134	N/A
12/31/2019	17	-149	-139	-139	N/A
9/30/2019	15	-122	-143	-120	N/A
6/30/2019	22	-113	-138	-115	N/A
3/31/2019	28	-89	-114	-91	N/A
12/31/2018	27	-72	-98	-75	N/A
9/30/2018	26	-79	-77	-76	N/A
6/30/2018	10	-81	-66	-65	N/A
3/31/2018	N/A	-76	-69	-69	N/A
12/31/2017	N/A	-68	-57	-57	N/A
9/30/2017	N/A	-61	N/A	-43	N/A
6/30/2017	N/A	-46	N/A	-37	N/A
3/31/2017	N/A	-41	N/A	-29	N/A
12/31/2016	N/A	-36	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-34	N/A
6/30/2016	N/A	-44	N/A	-39	N/A
3/31/2016	N/A	-51	N/A	-45	N/A
12/31/2015	N/A	-58	N/A	-46	N/A
9/30/2015	N/A	-60	N/A	-45	N/A
6/30/2015	N/A	-58	N/A	-43	N/A
3/31/2015	N/A	-55	N/A	-39	N/A
12/31/2014	N/A	-53	N/A	-37	N/A
9/30/2014	N/A	-51	N/A	-34	N/A
6/30/2014	N/A	-48	N/A	-32	N/A
3/31/2014	N/A	-45	N/A	-29	N/A
12/31/2013	N/A	-41	N/A	-26	N/A
9/30/2013	N/A	-38	N/A	-26	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0LOV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0LOV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0LOV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0LOV is forecast to have no revenue next year.

High Growth Revenue: 0LOV is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 0LOV's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Verastem Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2024

No longer forecast to breakeven

Forecast to breakeven in 2023

Recent updates

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Less than half of directors are independent

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021)

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

First quarter 2022 earnings released: US$0.091 loss per share (vs US$0.088 loss in 1Q 2021)

Less than half of directors are independent

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

Full year 2021 earnings released: US$0.41 loss per share (vs US$0.44 loss in FY 2020)

Verastem, Inc. Announces Management Changes

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.35 loss in 1Q 2020)

Verastem, Inc. Reports Updated Data from the LGSOC Cohort of the Ongoing, Investigator-Sponsored Phase 1/2 Frame Study Evaluating Vs-6766 in Combination with Defactinib in Patients with Recurrent LGSOC

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.00 loss in FY 2019)

Verastem, Inc. Appoints Frank Neumann as Chief Medical Officer

Verastem, Inc. Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Secura Bio, Inc. completed the acquisition of Global Commercial and Development Rights of COPIKTRA from Verastem, Inc. (NasdaqGM:VSTM).

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies